Evaluation of mucosal immune profile associated with Zileuton nanocrystal-formulated BCS-II drug upon oral administration in Sprague Dawley rats

References

• Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi, and S. Akira. 1998. “Targeted Disruption of the MyD88 Gene Results in Loss of IL-1- and IL-18-Mediated Function.” Immunity, 9 (1): 143–150. https://doi.org/10.1016/s1074-7613(00)80596-8.
   PubMed Web of Science ®Google Scholar
• Al-Sadi, R., S. Guo, D. Ye, M. Rawat, and T. Y. Ma. 2013. “TNF-Alpha Modulation of Intestinal Epithelial Tight Junction Barrier is Regulated by ERK1/2 Activation of Elk-1.” The American Journal of Pathology 186 (5): 1151–1165. https://doi.org/10.1016/j.ajpath.2015.12.016.
   Google Scholar
• Ansari, N., J. Abdulla, N. Zayyani, U. Brahmi, S. Taha, and A. A. Satir. 2006. “Comparison of RANTES Expression in Crohn’s Disease and Ulcerative Colitis: An Aid in the Differential Diagnosis?” Journal of Clinical Pathology 59 (10): 1066–1072. https://doi.org/10.1136/jcp.2005.034983.
   PubMed Web of Science ®Google Scholar
• Arrieta, M. C., K. Madsen, J. Doyle, and J. Meddings. 2009. “Reducing Small Intestinal Permeability Attenuates Colitis in the IL10 Gene-Deficient Mouse.” Gut 58 (1): 41–48. https://doi.org/10.1136/gut.2008.150888.
   PubMed Web of Science ®Google Scholar
• Bailie, M. B., L. J. Dahm, M. Peters-Golden, R. R. Harris, G. W. Carter, and R. A. Roth. 1995. “Leukotrienes and Alpha-Naphthylisothiocyanate-Induced Liver Injury.” Toxicology 100 (1–3): 139–149. https://doi.org/10.1016/0300-483x(95)03060-s.
   PubMed Web of Science ®Google Scholar
• Bertrán, X., J. Mañé, F. Fernández-Bañares, E. Castellá, R. Bartolí, I. Ojanguren, M. Esteve, and M. A. Gassull. 1996. “Intracolonic Administration of Zileuton, a Selective 5-Lipoxygenase Inhibitor, Accelerates Healing in a Rat Model of Chronic Colitis.” Gut 38 (6): 899–904. https://doi.org/10.1136/gut.38.6.899.
   PubMed Web of Science ®Google Scholar
• Blauvelt, A., and A. Chiricozzi. 2018. “The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis.” Clinical Reviews in Allergy & Immunology 55 (3): 379–390. https://doi.org/10.1007/s12016-018-8702-3.
   PubMed Web of Science ®Google Scholar
• Brusselle, G. G., T. Maes, and K. R. Bracke. 2013. “Eosinophils in the Spotlight: Eosinophilic Airway Inflammation in Nonallergic Asthma.” Nature Medicine 19 (8): 977–979. https://doi.org/10.1038/nm.3300.
   PubMed Web of Science ®Google Scholar
• Caracciolo, G. 2015. “Liposome-Protein Corona in a Physiological Environment: challenges and Opportunities for Targeted Delivery of Nanomedicines.” Nanomedicine: Nanotechnology, Biology, and Medicine 11 (3): 543–557. https://doi.org/10.1016/j.nano.2014.11.003.
   PubMed Web of Science ®Google Scholar
• Censi, R., and P. Di Martino. 2015. “Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs.” Molecules 20 (10): 18759–18776. https://doi.org/10.3390/molecules201018759.
   PubMed Web of Science ®Google Scholar
• Chesné, J., F. Braza, G. Chadeuf, G. Mahay, M.-A. Cheminant, J. Loy, S. Brouard, V. Sauzeau, G. Loirand, and A. Magnan. 2015. “Prime Role of IL-17A in Neutrophilia and Airway Smooth Muscle Contraction in a House Dust Mite-Induced Allergic Asthma Model.” The Journal of Allergy and Clinical Immunology 135 (6): 1643–1643 e3. https://doi.org/10.1016/j.jaci.2014.12.1872.
   PubMed Web of Science ®Google Scholar
• Chung, K. F. 2016. “Asthma Phenotyping: A Necessity for Improved Therapeutic Precision and New Targeted Therapies.” Journal of Internal Medicine 279 (2): 192–204. https://doi.org/10.1111/joim.12382.
   PubMed Web of Science ®Google Scholar
• Dahan, A., J. M. Miller, J. M. Hilfinger, S. Yamashita, L. X. Yu, H. Lennernäs, and G. L. Amidon. 2010. “High-Permeability Criterion for BCS Classification: Segmental/pH Dependent Permeability Considerations.” Molecular Pharmaceutics 7 (5): 1827–1834. https://doi.org/10.1021/mp100175a.
   PubMed Web of Science ®Google Scholar
• Dahlgren, D., and H. Lennernäs. 2019. “Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and in Vivo Approaches.” Pharmaceutics 11 (8): 411. https://doi.org/10.3390/pharmaceutics11080411.
   PubMed Web of Science ®Google Scholar
• Dionne, S., J. Hiscott, I. D'Agata, A. Duhaime, and E. G. Seidman. 1997. “Quantitative PCR Analysis of TNF-Alpha and IL-1 Beta mRNA Levels in Pediatric IBD Mucosal Biopsies.” Digestive Diseases and Sciences 42 (7): 1557–1566. https://doi.org/10.1023/a:1018895500721.
   PubMed Web of Science ®Google Scholar
• Ensign, L. M., R. Cone, and J. Hanes. 2012. “Oral Drug Delivery with Polymeric Nanoparticles: The Gastrointestinal Mucus Barriers.” Advanced Drug Delivery Reviews 64 (6): 557–570. https://doi.org/10.1016/j.addr.2011.12.009.
   PubMed Web of Science ®Google Scholar
• Fairstein, M., R. Swissa, and A. Dahan. 2013. “Regional-Dependent Intestinal Permeability and BCS Classification: elucidation of pH-Related Complexity in Rats Using Pseudoephedrine.” The AAPS Journal 15 (2): 589–597. https://doi.org/10.1208/s12248-013-9462-x.
   PubMed Web of Science ®Google Scholar
• Fuseini, H., and D. C. Newcomb. 2017. “Mechanisms Driving Gender Differences in Asthma.” Current Allergy and Asthma Reports 17 (3): 19. https://doi.org/10.1007/s11882-017-0686-1.
   PubMed Web of Science ®Google Scholar
• Gao, L., G. Liu, J. Ma, X. Wang, L. Zhou, X. Li, and F. Wang. 2013. “Application of Drug Nanocrystal Technologies on Oral Drug Delivery of Poorly Soluble Drugs.” Pharmaceutical Research 30 (2): 307–324. https://doi.org/10.1007/s11095-012-0889-z.
   PubMed Web of Science ®Google Scholar
• Giannakou, C., M. V. Park, W. H. de Jong, H. van Loveren, R. J. Vandebriel, and R. E. Geertsma. 2016. “A Comparison of Immunotoxic Effects of Nanomedicinal Products with Regulatory Immunotoxicity Testing Requirements.” International Journal of Nanomedicine 11: 2935–2952. https://doi.org/10.2147/IJN.S102385.
   PubMed Web of Science ®Google Scholar
• Gokulan, K., M. G. Arnold, J. Jensen, M. Vanlandingham, N. C. Twaddle, D. R. Doerge, C. E. Cerniglia, and S. Khare. 2018. “Exposure to Arsenite in CD-1 Mice during Juvenile and Adult Stages: Effects on Intestinal Microbiota and Gut-Associated Immune Status.” mBio 9 (4). https://doi.org/10.1128/mBio.01418-18.
   PubMed Web of Science ®Google Scholar
• Gounaris, E., M. J. Heiferman, J. R. Heiferman, M. Shrivastav, D. Vitello, N. R. Blatner, L. M. Knab, et al. 2015. “Zileuton, 5-Lipoxygenase Inhibitor, Acts as a Chemopreventive Agent in Intestinal Polyposis, by Modulating Polyp and Systemic Inflammation.” PLOS One 10 (3): e0121402. https://doi.org/10.1371/journal.pone.0121402.
   PubMed Web of Science ®Google Scholar
• Gupta, S., R. Kesarla, and A. Omri. 2013. “Formulation Strategies to Improve the Bioavailability of Poorly Absorbed Drugs with Special Emphasis on Self-Emulsifying Systems.” ISRN Pharmaceutics 2013: 848043. https://doi.org/10.1155/2013/848043.
   PubMedGoogle Scholar
• Hillaireau, H., and P. Couvreur. 2009. “Nanocarriers’ Entry into the Cell: Relevance to Drug Delivery.” Cellular and Molecular Life Sciences 66 (17): 2873–2896. https://doi.org/10.1007/s00018-009-0053-z.
   PubMed Web of Science ®Google Scholar
• Hinks, T. S. C., S. J. Levine, and G. G. Brusselle. 2021. “Treatment Options in Type-2 Low Asthma.” The European Respiratory Journal 57 (1): 2000528. https://doi.org/10.1183/13993003.00528-2020.
   PubMed Web of Science ®Google Scholar
• Hogan, S. P., P. S. Foster, X. Tan, and A. J. Ramsay. 1998. “Mucosal IL-12 Gene Delivery Inhibits Allergic Airways Disease and Restores Local Antiviral Immunity.” European Journal of Immunology 28 (2): 413–423. https://doi.org/10.1002/(SICI)1521-4141(199802)28:02<413::AID-IMMU413>3.0.CO;2-1.
   PubMed Web of Science ®Google Scholar
• Hollander, D. 1999. “Intestinal Permeability, Leaky Gut, and Intestinal Disorders.” Current Gastroenterology Reports 1 (5): 410–416. https://doi.org/10.1007/s11894-999-0023-5.
   PubMedGoogle Scholar
• Impellizzeri, D., R. Siracusa, M. Cordaro, A. F. Peritore, E. Gugliandolo, G. Mancuso, A. Midiri, R. Di Paola, and S. Cuzzocrea. 2018. “Therapeutic Potential of Dinitrobenzene Sulfonic Acid (DNBS)-Induced Colitis in Mice by Targeting IL-1beta and IL-18.” Biochemical Pharmacology 155: 150–161. https://doi.org/10.1016/j.bcp.2018.06.029.
   PubMed Web of Science ®Google Scholar
• Jarvis, M., V. Krishnan, and S. Mitragotri. 2019. “Nanocrystals: A Perspective on Translational Research and Clinical Studies.” Bioengineering & Translational Medicine 4 (1): 5–16. https://doi.org/10.1002/btm2.10122.
   PubMed Web of Science ®Google Scholar
• Jog, R., and D. J. Burgess. 2019. “Comprehensive Quality by Design Approach for Stable Nanocrystalline Drug Products.” International Journal of Pharmaceutics 564(: 426–460. https://doi.org/10.1016/j.ijpharm.2019.04.050.
   PubMed Web of Science ®Google Scholar
• Joshi, E. M., B. H. Heasley, M. D. Chordia, and T. L. Macdonald. 2004. “In Vitro Metabolism of 2-Acetylbenzothiophene: Relevance to Zileuton Hepatotoxicity.” Chemical Research in Toxicology 17 (2): 137–143. https://doi.org/10.1021/tx0341409.
   PubMed Web of Science ®Google Scholar
• Kim, B., Y. Lee, E. Kim, A. Kwak, S. Ryoo, S. H. Bae, T. Azam, S. Kim, and C. A. Dinarello. 2013. “The Interleukin-1alpha Precursor is Biologically Active and is Likely a Key Alarmin in the IL-1 Family of Cytokines.” Frontiers in Immunology 4: 391. https://doi.org/10.3389/fimmu.2013.00391.
   PubMed Web of Science ®Google Scholar
• Lamousé-Smith, E. S. N., and G. T. Furuta. 2006. “Eosinophils in the Gastrointestinal Tract.” Current Gastroenterology Reports 8 (5): 390–395. https://doi.org/10.1007/s11894-006-0024-6.
   PubMedGoogle Scholar
• Li, F., M. D. Chordia, K. A. Woodling, and T. L. Macdonald. 2007. “Irreversible Alkylation of Human Serum Albumin by Zileuton Metabolite 2-acetylbenzothiophene-S-Oxide: A Potential Model for Hepatotoxicity.” Chemical Research in Toxicology 20 (12): 1854–1861. https://doi.org/10.1021/tx7001417.
   PubMed Web of Science ®Google Scholar
• Lockman, P. R., J. M. Koziara, R. J. Mumper, and D. D. Allen. 2004. “Nanoparticle Surface Charges Alter Blood-Brain Barrier Integrity and Permeability.” Journal of Drug Targeting 12 (9–10): 635–641. https://doi.org/10.1080/10611860400015936.
   PubMed Web of Science ®Google Scholar
• Maeda, H., J. Wu, T. Sawa, Y. Matsumura, and K. Hori. 2000. “Tumor Vascular Permeability and the EPR Effect in Macromolecular Therapeutics: A Review.” Journal of Controlled Release65 (1–2): 271–284. https://doi.org/10.1016/s0168-3659(99)00248-5.
   PubMed Web of Science ®Google Scholar
• Mazzon, E., L. Sautebin, A. P. Caputi, and S. Cuzzocrea. 2006. “5-lipoxygenase Modulates the Alteration of Paracellular Barrier Function in Mice Ileum During Experimental Colitis.” Shock 25 (4): 377–383. https://doi.org/10.1097/01.shk.0000209530.30564.22.
   PubMed Web of Science ®Google Scholar
• Melstrom, L. G., D. J. Bentrem, M. R. Salabat, T. J. Kennedy, X. Z. Ding, M. Strouch, S. M. Rao, et al. 2008. “Overexpression of 5-Lipoxygenase in Colon Polyps and Cancer and the Effect of 5-LOX Inhibitors in Vitro and in a Murine Model.” Clinical Cancer Research 14 (20): 6525–6530. https://doi.org/10.1158/1078-0432.CCR-07-4631.
   PubMed Web of Science ®Google Scholar
• Mir, A., M. Minguez, J. Tatay, I. Pascual, A. Peña, V. Sanchiz, P. Almela, F. Mora, and A. Benages. 2002. “Elevated Serum Eotaxin Levels in Patients with Inflammatory Bowel Disease.” The American Journal of Gastroenterology 97 (6): 1452–1457. https://doi.org/10.1111/j.1572-0241.2002.05687.x.
   PubMed Web of Science ®Google Scholar
• Nagarwal, R. C., R. Kumar, M. Dhanawat, N. Das, and J. K. Pandit. 2011. “Nanocrystal Technology in the Delivery of Poorly Soluble Drugs: An Overview.” Current Drug Delivery 8 (4): 398–406. https://doi.org/10.2174/156720111795767988.
   PubMed Web of Science ®Google Scholar
• Nakamura, M., H. Saito, J. Kasanuki, Y. Tamura, and S. Yoshida. 1992. “Cytokine Production in Patients with Inflammatory Bowel Disease.” Gut 33 (7): 933–937. https://doi.org/10.1136/gut.33.7.933.
   PubMed Web of Science ®Google Scholar
• Nakanishi, K., T. Yoshimoto, H. Tsutsui, and H. Okamura. 2001. “Interleukin-18 Regulates Both Th1 and Th2 Responses.” Annual Review of Immunology 19 (1): 423–474. https://doi.org/10.1146/annurev.immunol.19.1.423.
   PubMedGoogle Scholar
• Nowarski, R., R. Jackson, N. Gagliani, M. R. de Zoete, N. W. Palm, W. Bailis, J. S. Low, et al. 2015. “Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis.” Cell 163 (6): 1444–1456. https://doi.org/10.1016/j.cell.2015.10.072.
   PubMed Web of Science ®Google Scholar
• Odenwald, M. A., and J. R. Turner. 2013. “Intestinal Permeability Defects: Is It Time to Treat?” Clinical Gastroenterology and Hepatology 11 (9): 1075–1083. https://doi.org/10.1016/j.cgh.2013.07.001.
   PubMed Web of Science ®Google Scholar
• Odenwald, M. A., and J. R. Turner. 2017. “The Intestinal Epithelial Barrier: A Therapeutic Target?” Nature Reviews. Gastroenterology & Hepatology 14 (1): 9–21. https://doi.org/10.1038/nrgastro.2016.169.
   PubMed Web of Science ®Google Scholar
• Oh, J. W., C. M. Seroogy, E. H. Meyer, O. Akbari, G. Berry, C. G. Fathman, R. H. Dekruyff, and D. T. Umetsu. 2002. “CD4 T-Helper Cells Engineered to Produce IL-10 Prevent Allergen-Induced Airway Hyperreactivity and Inflammation.” The Journal of Allergy and Clinical Immunology 110 (3): 460–468. https://doi.org/10.1067/mai.2002.127512.
   PubMed Web of Science ®Google Scholar
• Pan, H. F., R. X. Leng, and D. Q. Ye. 2011. “Lack of Association of Interleukin-18 Gene Promoter -607 a/C Polymorphism with Susceptibility to Autoimmune Diseases: A Meta-Analysis.” Lupus, 20 (9): 945–951. https://doi.org/10.1177/0961203311400114.
   PubMed Web of Science ®Google Scholar
• Pawar, V. K., Y. Singh, J. G. Meher, S. Gupta, and M. K. Chourasia. 2014. “Engineered Nanocrystal Technology: In-Vivo Fate, Targeting and Applications in Drug Delivery.” Journal of Controlled Release: official Journal of the Controlled Release Society 183: 51–66. https://doi.org/10.1016/j.jconrel.2014.03.030.
   PubMed Web of Science ®Google Scholar
• Powell, W. S., D. Chung, and S. Gravel. 1995. “5-Oxo-6,8,11,14-Eicosatetraenoic Acid is a Potent Stimulator of Human Eosinophil Migration.” Journal of Immunology 154 (8): 4123–4132. https://doi.org/10.4049/jimmunol.154.8.4123.
   PubMed Web of Science ®Google Scholar
• Pridgen, E. M., F. Alexis, and O. C. Farokhzad. 2015. “Polymeric Nanoparticle Drug Delivery Technologies for Oral Delivery Applications.” Expert Opinion on Drug Delivery 12 (9): 1459–1473. https://doi.org/10.1517/17425247.2015.1018175.
   PubMed Web of Science ®Google Scholar
• Qiu, Y., H. W. Hui, and H. Cheskin. 1997. “Formulation Development of Sustained-Release Hydrophilic Matrix Tablets of Zileuton.” Pharmaceutical Development and Technology 2 (3): 197–204. https://doi.org/10.3109/10837459709031439.
   PubMedGoogle Scholar
• Reinecker, H. C., M. Steffen, T. Witthoeft, I. Pflueger, S. Schreiber, R. P. MacDermott, and A. Raedler. 1993. “Enhanced Secretion of Tumour Necrosis Factor-Alpha, IL-6, and IL-1 Beta by Isolated Lamina Propria Mononuclear Cells from Patients with Ulcerative Colitis and Crohn’s Disease.” Clinical and Experimental Immunology 94 (1): 174–181. https://doi.org/10.1111/j.1365-2249.1993.tb05997.x.
   PubMed Web of Science ®Google Scholar
• Rodrigues, A. D., and J. M. Machinist. 1996. “Hepatic Peroxisomal and Drug Metabolizing Activity in CD-1 Mice after Oral Treatment with a Novel 5-Lipoxygenase Inhibitor.” Toxicology and Applied Pharmacology 137 (2): 193–201. https://doi.org/10.1006/taap.1996.0072.
   PubMed Web of Science ®Google Scholar
• Rosenstreich, D. L., S. N. Vogel, A. R. Jacques, L. M. Wahl, and J. J. Oppenheim. 1978. “Macrophage Sensitivity to Endotoxin: genetic Control by a Single Codominant Gene.” The Journal of Immunology 121 (5): 1664–1670. https://doi.org/10.4049/jimmunol.121.5.1664.
   PubMed Web of Science ®Google Scholar
• Salcedo, R., A. Worschech, M. Cardone, Y. Jones, Z. Gyulai, R. M. Dai, E. Wang, et al. 2010. “MyD88-Mediated Signaling Prevents Development of Adenocarcinomas of the Colon: Role of Interleukin 18.” The Journal of Experimental Medicine 207 (8): 1625–1636. https://doi.org/10.1084/jem.20100199.
   PubMed Web of Science ®Google Scholar
• Sawada, M., T. Kawayama, H. Imaoka, Y. Sakazaki, H. Oda, S. Takenaka, Y. Kaku, et al. 2013. “IL-18 Induces Airway Hyperresponsiveness and Pulmonary Inflammation via CD4+ T Cell and IL-13.” PLOS One, 8 (1): e54623. https://doi.org/10.1371/journal.pone.0054623.
   PubMed Web of Science ®Google Scholar
• Scaldaferri, F., M. Pizzoferrato, V. Gerardi, L. Lopetuso, and A. Gasbarrini. 2012. “The Gut Barrier: new Acquisitions and Therapeutic Approaches.” Journal of Clinical Gastroenterology 46 (Suppl): S12–S7. https://doi.org/10.1097/MCG.0b013e31826ae849.
   PubMedGoogle Scholar
• Schäfer, V., H. von Briesen, R. Andreesen, A. M. Steffan, C. Royer, S. Tröster, J. Kreuter, and H. Rübsamen-Waigmann. 1992. “Phagocytosis of Nanoparticles by Human Immunodeficiency Virus (HIV)-Infected Macrophages: A Possibility for Antiviral Drug Targeting.” Pharmaceutical Research 9 (4): 541–546. https://doi.org/10.1023/a:1015852732512.
   PubMed Web of Science ®Google Scholar
• Schatz, M., and C. A. Camargo. Jr. 2003. “The Relationship of Sex to Asthma Prevalence, Health Care Utilization, and Medications in a Large Managed Care Organization.” Annals of Allergy, Asthma & Immunology 91 (6): 553–558. https://doi.org/10.1016/S1081-1206(10)61533-5.
   PubMed Web of Science ®Google Scholar
• Shan, X., X. Gong, J. Li, J. Wen, Y. Li, and Z. Zhang. 2022. “Current Approaches of Nanomedicines in the Market and Various Stage of Clinical Translation.” Acta Pharmaceutica Sinica B 12 (7): 3028–3048. https://doi.org/10.1016/j.apsb.2022.02.025.
   PubMed Web of Science ®Google Scholar
• Shegokar, R., and R. H. Müller. 2010. “Nanocrystals: industrially Feasible Multifunctional Formulation Technology for Poorly Soluble Actives.” International Journal of Pharmaceutics 399 (1–2): 129–139. https://doi.org/10.1016/j.ijpharm.2010.07.044.
   PubMed Web of Science ®Google Scholar
• Sivakumar, P. V., G. M. Westrich, S. Kanaly, K. Garka, T. L. Born, J. M. Derry, and J. L. Viney. 2002. “Interleukin 18 is a Primary Mediator of the Inflammation Associated with Dextran Sulphate Sodium Induced Colitis: blocking Interleukin 18 Attenuates Intestinal Damage.” Gut 50 (6): 812–820. https://doi.org/10.1136/gut.50.6.812.
   PubMed Web of Science ®Google Scholar
• Soman, K. V., S. J. Stafford, K. Pazdrak, Z. Wu, X. Luo, W. I. White, J. E. Wiktorowicz, W. J. Calhoun, and A. Kurosky. 2017. “Activation of Human Peripheral Blood Eosinophils by Cytokines in a Comparative Time-Course Proteomic/Phosphoproteomic Study.” Journal of Proteome Research 16 (8): 2663–2679. https://doi.org/10.1021/acs.jproteome.6b00367.
   PubMed Web of Science ®Google Scholar
• Sorkness, C. A. 1997. “The Use of 5-Lipoxygenase Inhibitors and Leukotriene Receptor Antagonists in the Treatment of Chronic Asthma.” Pharmacotherapy17 (1P2): 50S–54S. https://doi.org/10.1002/j.1875-9114.1997.tb03701.x.
   PubMedGoogle Scholar
• Soumaoro, L. T., S. Iida, H. Uetake, M. Ishiguro, Y. Takagi, T. Higuchi, M. Yasuno, M. Enomoto, and K. Sugihara. 2006. “Expression of 5-Lipoxygenase in Human Colorectal Cancer.” World Journal of Gastroenterology 12 (39): 6355–6360. https://doi.org/10.3748/wjg.v12.i39.6355.
   PubMed Web of Science ®Google Scholar
• Su, H., Y. Wang, Y. Gu, L. Bowman, J. Zhao, and M. Ding. 2018. “Potential Applications and Human Biosafety of Nanomaterials Used in Nanomedicine.” Journal of Applied Toxicology 38 (1): 3–24. https://doi.org/10.1002/jat.3476.
   PubMed Web of Science ®Google Scholar
• Subrakova, V. G., S. V. Kulemzin, T. N. Belovezhets, A. N. Chikaev, N. A. Chikaev, O. A. Koval, A. A. Gorchakov, and A. V. Taranin. 2020. “Shp-2 Gene Knockout Upregulates CAR-Driven Cytotoxicity of YT NK Cells.” Vavilovskii Zhurnal Genetiki i Selektsii 24 (1): 80–86. https://doi.org/10.18699/VJ20.598.
   PubMed Web of Science ®Google Scholar
• Suenaert, P., V. Bulteel, L. Lemmens, M. Noman, B. Geypens, G. Van Assche, K. Geboes, J. L. Ceuppens, and P. Rutgeerts. 2002. “Anti-Tumor Necrosis Factor Treatment Restores the Gut Barrier in Crohn’s Disease.” The American Journal of Gastroenterology 97 (8): 2000–2004. https://doi.org/10.1111/j.1572-0241.2002.05914.x.
   PubMed Web of Science ®Google Scholar
• Tanaka, H., M. Komai, K. Nagao, M. Ishizaki, D. Kajiwara, K. Takatsu, G. Delespesse, and H. Nagai. 2004. “Role of Interleukin-5 and Eosinophils in Allergen-Induced Airway Remodeling in Mice.” American Journal of Respiratory Cell and Molecular Biology 31 (1): 62–68. https://doi.org/10.1165/rcmb.2003-0305OC.
   PubMed Web of Science ®Google Scholar
• Tanaka, H., N. Miyazaki, K. Oashi, S. Teramoto, M. Shiratori, M. Hashimoto, M. Ohmichi, and S. Abe. 2001. “IL-18 Might Reflect Disease Activity in Mild and Moderate Asthma Exacerbation.” The Journal of Allergy and Clinical Immunology 107 (2): 331–336. https://doi.org/10.1067/mai.2001.112275.
   PubMed Web of Science ®Google Scholar
• Umetsu, D. T., and R. H. DeKruyff. 1997. “TH1 and TH2 CD4+ Cells in Human Allergic Diseases.” The Journal of Allergy and Clinical Immunology 100 (1): 1–6. https://doi.org/10.1016/s0091-6749(97)70186-6.
   PubMed Web of Science ®Google Scholar
• van Scott, M. R., J. P. Justice, J. F. Bradfield, E. Enright, A. Sigounas, and S. Sur. 2000. “IL-10 Reduces Th2 Cytokine Production and Eosinophilia but Augments Airway Reactivity in Allergic Mice.” American Journal of Physiology - Lung Cellular and Molecular Physiology 278 (4): L667–74. https://doi.org/10.1152/ajplung.2000.278.4.L667.
   PubMed Web of Science ®Google Scholar
• Veenbergen, S., R. L. Smeets, M. B. Bennink, O. J. Arntz, L. A. Joosten, W. B. van den Berg, and F. A. van de Loo. 2010. “The Natural Soluble Form of IL-18 Receptor Beta Exacerbates Collagen-Induced Arthritis via Modulation of T-Cell Immune Responses.” Annals of the Rheumatic Diseases 69 (1): 276–283. https://doi.org/10.1136/ard.2008.100867.
   PubMed Web of Science ®Google Scholar
• Wang, E., M. E. Wechsler, T. N. Tran, L. G. Heaney, R. C. Jones, A. N. Menzies-Gow, J. Busby, et al. 2020. “Characterization of Severe Asthma Worldwide: Data from the International Severe Asthma Registry.” Chest 157 (4): 790–804. https://doi.org/10.1016/j.chest.2019.10.053.
   PubMed Web of Science ®Google Scholar
• Watkins, P. B., L. M. Dube, K. Walton-Bowen, C. M. Cameron, and L. E. Kasten. 2007. “Clinical Pattern of Zileuton-Associated Liver Injury: results of a 12-Month Study in Patients with Chronic Asthma.” Drug Safety 30 (9): 805–815. https://doi.org/10.2165/00002018-200730090-00006.
   PubMed Web of Science ®Google Scholar
• You, D., L. E. Lyn-Cook, D. M. Gatti, N. Bell, P. R. Mayeux, L. P. James, W. B. Mattes, G. J. Larson, and A. H. Harrill. 2020. “Nitrosative Stress and Lipid Homeostasis as a Mechanism for Zileuton Hepatotoxicity and Resistance in Genetically Sensitive Mice.” Toxicological Sciences 175 (2): 220–235. https://doi.org/10.1093/toxsci/kfaa037.
   PubMed Web of Science ®Google Scholar
• Youn, J. I., and D. I. Gabrilovich. 2010. “The Biology of Myeloid-Derived Suppressor Cells: The Blessing and the Curse of Morphological and Functional Heterogeneity.” European Journal of Immunology 40 (11): 2969–2975. https://doi.org/10.1002/eji.201040895.
   PubMed Web of Science ®Google Scholar
• Zaki, M. H., M. Lamkanfi, and T. D. Kanneganti. 2011. “The Nlrp3 Inflammasome: Contributions to Intestinal Homeostasis.” Trends in Immunology 32 (4): 171–179. https://doi.org/10.1016/j.it.2011.02.002.
   PubMed Web of Science ®Google Scholar
• Zarif, A., D. Eiznhamer, C. Callaghan, M. I. Doria, L. Broutman, and A. Keshavarzian. 1996. “The Effect of a Selective 5-Lipoxygenase Inhibitor, Zileuton, on Tissue Damage in Acute Colonic Inflammation in Rats.” Inflammation 20 (3): 217–227. https://doi.org/10.1007/BF01488200.
   PubMed Web of Science ®Google Scholar
• Zolnik, B. S., A. González-Fernández, N. Sadrieh, and M. A. Dobrovolskaia. 2010. “Nanoparticles and the Immune System.” Endocrinology 151 (2): 458–465. https://doi.org/10.1210/en.2009-1082.
   PubMed Web of Science ®Google Scholar